|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| 10-02 | Major drugmakers turn to China for licensing deals | RE |
| 10-01 | GSK plc : JP Morgan reiterates its Sell rating | ZD |
| Market Cap | 71.3B 94.34B 83.82B 78.23B 134B 9,069B 136B 947B 367B 4,636B 354B 347B 14,879B | P/E 2026 * |
13.8x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 92.55B 122B 109B 102B 175B 11,771B 176B 1,229B 476B 6,017B 460B 450B 19,312B | EV / Sales 2026 * |
2.73x | EV / Sales 2027 * | 2.53x |
| Free-Float |
92.75% | Yield 2026 * |
3.91% | Yield 2027 * | 4.21% |
Last Transcript: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.61% | -3.43% | +36.07% | +115.04% | 1,019B | |
| -1.02% | -5.60% | +35.72% | +64.63% | 617B | |
| +1.11% | -0.58% | +12.36% | +77.95% | 464B | |
| +0.34% | -3.01% | +61.79% | +41.24% | 356B | |
| -0.95% | -4.05% | +20.54% | +41.71% | 333B | |
| -1.46% | -2.89% | +10.57% | +32.81% | 267B | |
| -1.35% | -5.43% | -6.17% | +8.98% | 244B | |
| -1.04% | -2.79% | +35.30% | +51.84% | 218B | |
| -1.87% | -4.10% | +28.44% | +93.66% | 179B | |
| Average | -0.76% | -3.54% | +26.07% | +58.65% | 410.8B | |
| Weighted average by Cap. | -0.60% | -3.54% | +29.07% | +70.57% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.92B 44.88B 39.87B 37.21B 63.97B 4,314B 64.57B 450B 175B 2,205B 168B 165B 7,078B | 35.5B 46.96B 41.73B 38.95B 66.95B 4,515B 67.57B 471B 183B 2,308B 176B 172B 7,407B |
| Net income | 5.19B 6.87B 6.1B 5.7B 9.79B 660B 9.88B 68.93B 26.71B 338B 25.79B 25.23B 1,083B | 6.21B 8.22B 7.3B 6.81B 11.71B 790B 11.82B 82.44B 31.95B 404B 30.84B 30.17B 1,296B |
| Net Debt | 21.24B 28.1B 24.97B 23.31B 40.06B 2,702B 40.44B 282B 109B 1,381B 106B 103B 4,433B | 18.52B 24.5B 21.77B 20.32B 34.92B 2,355B 35.25B 246B 95.27B 1,204B 91.98B 89.98B 3,864B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
